Potassium humate inhibits complement activation and the production of inflammatory cytokines in vitro

Inflammation

Volumn 32, Issue 4, 2009, Pages 270-276

  Jansen Van Rensburg, Constance E ^a   Naude, Pieter J ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Anti inflammatory; Complement activation; Cytokines; Potassium humate

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENT; HUMATE POTASSIUM; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHYTOHEMAGGLUTININ; PHYTOHEMAGGLUTININ A; POKEWEED MITOGEN; POTASSIUM DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ERYTHROCYTE MEMBRANE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; MONONUCLEAR LYMPHOCYTE; NORMAL HUMAN; POKEWEED;

CELL PROLIFERATION; COAL; COMPLEMENT ACTIVATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HUMIC SUBSTANCES; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTES;

PHYTOLACCACEAE;

EID: 67651225135     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-009-9130-6     Document Type: Article

References (24)

1. I. Schepetkin A. Khlebnikov B. S. Kwon 2002 Medical drugs from humus matter: focus on mumie Drug Dev. Res. 57 140 159
2. J. J. Bergh I. J. Cronje J. Dekker T. G. Dekker L. M. Gerritsma L. J. Mienie 1997 Non-catalytic oxidation of water-slurried coal with oxygen: identification of fulvic acids and acute toxicity Fuel 76 149 154
3. G. K. Jooné J. Dekker C. E. J. van Rensburg 2003 Investigation of the immunostimulatory properties of oxihumate Z. Naturforsch. 58 263 267
4. G. K. Joonék C. E. J. Rensburg 2004 An in vitro investigation of the anti-inflammatory properties of potassium humate Inflammation 28 169 174
5. C. E. J. Van Rensburg J. R. Snyman T. Mokoele A. D. Cromarty 2007 Brown coal derived humate inhibits contact hypersensitivity; an efficacy, toxicity and teragenicity study in rats Inflammation 30 148 152
6. T. R. Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 37 64
7. C. E. J. Van Rensburg R. Anderson M. S. Myer G. K. Jooné J. F. O'Sullivan 1994 The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line Cancer Lett. 85 59 63
8. T. A. E. Platts-Mills K. Ishizaka 1976 Activation of the alternate pathway of human complement by rabbit cells J. Immunol. 113 348 358
9. + subset Exp. Med. 187 1885 1892
10. Cooper, N. R. 1999. Biology of the complement system. In: Inflammation. Basic Principles and Clinical Correlates, Gallin, J. L., and R. Snyderman eds. 3rdLippincott Williams & Wilkins, Philadelphia, pp. 281-315.
11. M. Kirschfink 1997 Controlling the complement system in inflammation Immunopharmacology 38 51 62
12. M. A. Hietala K. S. Nandakumar L. Persson S. Fahlen R. Holmdahl M. Pekna 2004 Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis Eur. J. Immunol. 34 1208 1216
13. R. Nijmeijer W. K. Lagrand C. A. Visser C. J. L. M. Meijer H. W. M. Niessen C. E. Hack 2001 CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int. Immunopharmacol. 1 403 414
14. S. M. Drouin D. B. Corry J. Kildsgaard R. A. Wetsel 2001 Cutting edge: the absence of C3 demonstrates a role for complement in Th1 effector functions in a murine model of pulmonary allergy J. Immunol. 167 4141 4145
15. W. P. Arend J. Dayer 1995 Inhibition of the production and effects of inteleukin-1 and tumour nucrosis factor α in rheumatoid arthritis Arthritis Rheum. 38 151 160
16. P. Charles M. J. Elliott D. Davis A. Potter J. R. Kalden C. Antoni F. C. Breedveld J. S. Smolen G. Eberl K. deWoody M. Feldmann R. N. Maini 1999 Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-therapy in rheumatoid arthritis J. Immunol. 163 1521 1528
17. C. Gabay 2002 Cytokine inhibitors in the treatment of rheumatoid arthritis Expert Opin. Biol. Ther. 2 135 149
18. L. H. Calabresel 2003 Molecular differences in anticytokine therapies Clin. Exp. Rheumatol. 21 241 248
19. A. A. Fitzgerald S. A. LeCercq A. Yan J. E. Homik C. A. Dinarello 2005 Rapid responses to anakinra in patients with refractory adult-onset of Still's disease Arthritis Rheum. 52 1794 1803
20. H. M. Van Dulleman S. J. H. Van Deventer D. W. Hommes H. A. Bijl J. Jansen G. N. J. Tytgat J. Woody 1995 Treatment of Crohn's disease with antitumour necrosis factor chimeric antibody (cA2) Gastroenterology 109 129 135
21. 2-dependent mechanisms J. Immunol. 171 2631 2636
22. TM, Bangkok, Thailand. Including the 10th WPAS in conjunction with the 7th Asian Pacific Congress of Allergology, Asthma and Clinical Immunology. 2-6 December 2007.
23. Badenhorst, B. E., C. E. J. van Rensburg, J. R. Snyman, and P. J. Becker. 2008. Humic acid reduces inflammation in patients with osteoarthritis. South African Society for Basic and Clinical Pharmacology Congress. Rhodes, 5-8 October 2008.
24. A. D. Corcia A. Costantino C. Crescenzi R. Samperi 1999 Quantification of phenylurea herbicides and their free and humic acid-associated metabolite in natural waters J. Chromatogr. A. 852 465 74